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Abstract 
Background: Neovascularization, a distinguishing trait of high-grade glioma, is a target for anti-angiogenic treat-
ment with bevacizumab (BEV). This study sought to use ferumoxytol-based dynamic susceptibility contrast magnetic 
resonance imaging (MRI) to clarify perfusion and relative blood volume (rCBV) changes in glioma treated with BEV 
and to determine potential impact on clinical management.
Methods: 16 high grade glioma patients who received BEV following post-chemoradiation radiographic or clinical 
progression were included. Ferumoxytol-based MRI perfusion measurements were taken before and after BEV. Lesions 
were defined at each timepoint by gadolinium-based contrast agent (GBCA)-enhancing area. Lesion volume and rCBV 
were compared pre and post-BEV in the lesion and rCBV “hot spot” (mean of the highest rCBV in a 1.08 cm2 area in the 
enhancing volume), as well as hypoperfused and hyperperfused subvolumes within the GBCA-enhancing lesion.
Results: GBCA-enhancing lesion volumes decreased 39% (P = 0.01) after BEV. Mean rCBV in post-BEV GBCA-enhanc-
ing area did not decrease significantly (P = 0.227) but significantly decreased in the hot spot (P = 0.046). Mean and 
hot spot rCBV decreased (P = 0.039 and 0.007) when post-BEV rCBV was calculated over the pre-BEV GBCA-enhanc-
ing area. Hypoperfused pixel count increased from 24% to 38 (P = 0.007) and hyperperfused decreased from 39 to 
28% (P = 0.017). Mean rCBV decreased in 7/16 (44%) patients from >1.75 to <1.75, the cutoff for pseudoprogression 
diagnosis.
Conclusions: Decreased perfusion after BEV significantly alters rCBV measurements when using ferumoxytol. BEV 
treatment response hinders efforts to differentiate true progression from pseudoprogression using blood volume 
measurements in malignant glioma, potentially impacting patient diagnosis and management.
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Background
Treatment for newly diagnosed glioblastoma (GBM) 
consists of resection followed by radiotherapy with con-
comitant temozolomide (TMZ). Increased enhancement 
volume on T1-weighted magnetic resonance imaging 
(MRI) using gadolinium-based contrast agent (GBCA) 
after chemoradiotherapy (CRT) in GBM patients can rep-
resent tumor progression or pseudoprogression. Diag-
nostic accuracy is critical in deciding appropriate therapy. 
Response assessment in neuro-oncology (RANO) sug-
gests that differentiation of pseudoprogression from 
disease progression cannot be accomplished with a con-
ventional MRI method in the first 12 weeks post-CRT [1].
Ferumoxytol, an iron oxide nanoparticle, is FDA-
approved for iron replacement and used off-label for 
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brain imaging, especially in patients with compromised 
renal function for whom GBCA is contraindicated [2]. 
Ferumoxytol as an MRI contrast agent for perfusion 
benefits from its intravascular property. Compared to 
GBCA, it may not require leakage correction or preload 
dosing [3]. Perfusion MRI has been used clinically as a 
biomarker to prospectively differentiate pseudoprogres-
sion from disease progression [4–7], and relative cerebral 
blood volume (rCBV) measurements using ferumoxy-
tol as an MRI contrast agent can discriminate true pro-
gression from pseudoprogression in GBM using a mean 
rCBV threshold of 1.75 [3, 8]. The use of small paramag-
netic iron oxides (SPIOs), such as ferumoxytol, was first 
published as an MR-based imaging agent for cancer in 
1989, and has increased exponentially in the last dec-
ade. There were 728 publications on SPIOs and cancer 
between 1990 and 2010 and more than 864 in the last five 
years alone.
Bevacizumab (BEV) is an anti-vascular endothelial 
growth factor (VEGF) A antibody working as an angio-
genesis inhibitor [9] that normalizes tumor vasculature 
[10], and decreases contrast-enhancing tumor volume 
and blood volume in lesions both in animal models [11, 
12] and clinically [13–15]. No association has been found 
between tumor volume change after BEV and overall or 
progression-free survival [16]. After treatment with BEV, 
tumor perfusion decreases but tumor growth may only 
be temporarily inhibited [17, 18], leading to “pseudor-
esponse” and mismanaged therapy. Due to the likelihood 
of pseudoresponse and normalization of the blood–brain 
barrier, traditional methods to assess post-CRT tumor 
progression can be misleading in patients treated with 
BEV [1], and there is a concern that evaluating CBV for 
differentiating real progression from pseudoprogression 
as a result of CRT after treatment with BEV may pro-
duce false negative results. This study hypothesizes that 
perfusion decrease in high grade tumors after CRT and 
subsequent treatment with BEV can affect clinical man-
agement, and aimed to determine rCBV changes post-
BEV using ferumoxytol-based dynamic susceptibility 
contrast (DSC) MR perfusion in patients with high grade 
glioma in a clinical setting.
Methods
Data collection
Sixteen patients (mean age in years [range]: 54 [39–63]; 
6 males, 53 [44–62]; 10 females, 52 [43–61]) presenting 
with a total of 21 lesions (5 patients had two distinct and 
isolated lesions) were included in this retrospective study 
and provided written informed consent on one of four 
prospective Oregon Health & Science University HIPAA-
compliant and IRB-approved MRI protocols (2753, 2864, 
1562, and 813) using two contrast agents, GBCA and 
ferumoxytol, between 2009 and 2012. On average, pre-
BEV MRI studies were performed 7  days (range: 0–21) 
before drug infusion, and post-treatment MRIs were per-
formed 27 days after (range: 12–30).
Inclusion criteria were that patients have histological 
evidence of high grade glioma; evidence of increased or 
new enhancing tumor on clinical scan, which at time of 
scan could have represented tumor progression or treat-
ment related changes; having received CRT and bevaci-
zumab in the course of disease treatment; and an MRI 
study with gadoteridol and ferumoxytol DSC MRI less 
than 21 days before BEV and less than 30 days after. All 
patients received standard CRT with either 60 Gy in 30 
fractions or 59.4  Gy in 33 fractions, with concomitant 
oral TMZ at a dose of 75  mg/m2/day. After completion 
of CRT all patients continued on monthly TMZ (150–
200  mg/m2/day for 5 days in every 28  day cycle) for at 
least 6 months or until disease progression occurred [19].
Imaging
Patients underwent 3T MRI (Siemens Trio or Philips 
Achieva) with a multichannel head coil. All imaging 
protocols included anatomical and dynamic sequences 
in the axial plane. T1-weighted scans (repetition time 
[TR]/echo time [TE]  ≈ 900  ms/10  ms, field of view 
[FOV]  =  240  mm2, matrix  =  256  ×  256,  ~44 2  mm 
slices with no gap) were acquired with a standard dose of 
0.1 mmol/kg intravenous (IV) gadoteridol to assess con-
trast enhancing volume. DSC scans (90 measurements 
at 0.66  Hz, TR/TE/flip angle  =  1500  ms/20  ms/45°, 
FOV = 192 mm2, matrix 64 × 64, 27 3 mm slices with a 
0.9 mm gap) were acquired, with a short IV bolus of 1 or 
2 mg/kg (~5–10 ml) ferumoxytol injected at a flow rate of 
3 ml/s followed by 20 ml of saline flush at the same rate. 
Approximately 20 measurements were obtained before 
the contrast reached the brain allowing an accurate base-
line signal. Patients did not receive ferumoxytol directly 
after gadoteridol; in some cases, the two agents and their 
associated imaging acquisitions were separated by at least 
12  min, and in some cases the acquisitions took place 
during sessions on consecutive days. However, recent 
work has shown that dual contrast sessions are feasible 
and yield reliable measurements of rCBV [20].
Image analysis
Tumor volume measurements were taken as the prod-
uct of the extent of the GBCA-enhancing areas in three 
orthogonal axes as measured by a neuroradiologist with 
8 years of experience (JPN). All DSC data were processed 
by JPN using NordicICE. CBV maps were generated by 
applying a tracer kinetic model to the first pass of the 
contrast bolus. Voxelwise CBV maps were coregistered 
to T1-weighted images and then normalized by dividing 
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by the mean of normal appearing white matter CBV in 
the same region in the contralateral hemisphere (rCBV), 
defined by JPN and chosen in the same axial slice as the 
lesion when possible, or if not possible, in the most proxi-
mal axial slice to the lesion.
One region of interest (ROI) was drawn on each 
GBCA-enhancing lesion (JPN) pre- (ROIpre) and post-
BEV (ROIpost) in each patient. The slice with the largest 
enhancing area was chosen based on the standard clinical 
evaluation for brain tumor assessment (RANO criteria) 
[1]. Care was taken to exclude blood vessels and areas of 
cystic change or necrosis, defined as abnormal areas with 
hyperintense signal on T2-weighted and hypointense 
signal on T1-weighted without discernible enhancement 
after GBCA injection.
Mean tumor rCBV, the voxelwise ferumoxytol-based 
DSC measurement, was calculated over each GBCA-
enhancing ROI. Three means were calculated: (1) pre-
BEV rCBV over ROIpre, (2) post-BEV rCBV over ROIpost, 
and (3) post-BEV rCBV over ROIpre. The third mean 
was calculated because BEV caused an expected reduc-
tion in the extent of GBCA enhancement, likely due to a 
reduction in vascular permeability secondary to vascular 
normalization; however, changes in local blood volume 
due to BEV likely occur beyond the extent of post-BEV 
GBCA enhancement.
The mean of “hot spot” (the mean of the highest rCBV 
in a 1.08 cm2 area in the enhancing volume, the default 
size of a standard circular region of interest in Nordic 
ICE) rCBV values and pixel-wise rCBV histograms were 
obtained for each ROI. A standardized (% voxels in each 
bin/total voxels) histogram was determined using 40 bins 
0.25 wide (range: 0–10). The proportion of voxels with 
rCBV > 1.75 was defined as hyperperfused subvolumes. 
This threshold value provides the optimal sensitivity and 
specificity for differentiating low grade from high grade 
glioma using rCBV [21]; it also has been used to differ-
entiate treatment related changes and true progression 
using ferumoxytol or leakage-corrected GBCA perfusion 
MRI [3]. There is no established threshold for delineating 
hypoperfused subvolumes [15]. rCBV ≤  0.75 was used, 
which represents perfusion at least 25% lower than nor-
mal appearing contralateral white matter.
A linear mixed effects model was used to compare dif-
ferences in enhancing volume, mean and hot spot rCBVs, 
as well as hyperperfused and hypoperfused subvolumes 
before versus after BEV while taking into the account 
observations within the same patient. The Dunnett-Hsu 
method was used to adjust for multiple comparisons with 
the before BEV period as the control group. Least square 
(LS) mean ± standard error (SE) are reported. To assess 
the likelihood of BEV treatment to affect diagnostic crite-
ria and clinical management, the proportion of patients 
with lesions that changed from high rCBV (≥1.75) before 
BEV to low rCBV (<1.75) after BEV was also calculated. 
For patients with two lesions, if both lesions changed 
from high to low rCBV, or one lesion changed from high 
to low and the other lesion remained low before versus 
after BEV, it was counted as a change that would likely 
impact clinical management. If one lesion changed from 
high to low and the other lesion remained high, it was 
not counted as a change that would likely impact clinical 
management. All analyses were conducted using SAS 9.3 
(SAS Institute Inc., Cary, NC, USA.).
Results
Fourteen patients were diagnosed with GBM, one with 
anaplastic astrocytoma, and one with anaplastic oligo-
dendroglioma. Patients received BEV due to increasing 
enhancing lesion without clinical symptoms in 8 (50%) 
cases, increasing enhancing lesion with clinical symp-
toms in 7 (44%) cases, and clinical worsening but radio-
graphically stable disease in 1 (6%) case.
After BEV treatment, 18 out of 21 (86%) GBCA-
enhanced T1-weighted tumor volumes decreased. The 
mean volume was significantly smaller post-BEV, decreas-
ing approximately 39% (pre-BEV, 55,807  mm3  ±  11,422; 
post-BEV 34,474 mm3 ± 11,422; P = 0.005, Fig. 1, exempli-
fied in patient in Fig. 2).
When examining perfusion measurements in each lesion 
after BEV treatment, there was no significant difference 
in mean rCBV values in ROIpre vs. ROIpost (1.95 ±  0.35–
1.65  ±  0.32, respectively, P  =  0.227, Fig.  3a). However, 
mean “hot spot” rCBV decreased between pre- and post-
BEV (4.04  ±  0.64–3.13  ±  0.52, respectively, P  =  0.046, 
Fig. 3c). When post-BEV rCBV values averaged over ROIpre 
were compared to pre-BEV mean rCBV values over ROIpre, 
mean and “hot spot” values decreased to 1.51  ±  0.30 
(P = 0.039, Fig. 3b), and 2.81 ± 0.52 (P = 0.007, Fig. 3d), 
respectively. The relationship between rCBV changes and 
timing of the scan with respect to BEV administration was 
tested with Pearson’s r. There were no significant findings in 
hot spot or mean rCBV analyses (Fig. 4).
For the assessment of the likelihood of BEV treatment 
to affect diagnostic criteria and clinical management, 
7/16 (44%) patients had lesions that changed from high 
rCBV (≥1.75) to low rCBV (<1.75) when mean pre-BEV 
rCBV values over ROIpre were compared to mean rCBV 
post-BEV over ROIpost (Fig.  3a: red lines). In addition, 
2/16 (13%) patients had lesions that changed from low 
rCBV (<1.75) to high rCBV (≥1.75). Similarly, when cal-
culating post-BEV rCBV over ROIpre, 7/16 (44%) changed 
from high to low rCBV (Fig. 3b: red lines), and one (6%) 
changed from low to high rCBV.
More detailed examination of rCBV changes was 
accomplished through distribution analysis. The average 
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histogram in ROIpost vs. ROIpre demonstrated a signifi-
cant increase in the mean proportion of hypoperfused 
voxels from 24% pre-BEV to 38% post-BEV (P = 0.0007), 
and a significant decrease in hyperperfused voxels from 
39% pre-BEV to 28% post-BEV (P  =  0.017, Fig.  5: gray 
vs. blue). Similarly, when the histogram of post-BEV 
rCBV was generated over ROIpre, the mean proportion 
of hypoperfused voxels increased to 41% from pre-BEV 
(P = 0.0001), and the mean proportion of hyperperfused 
voxels decreased to 26% (P = 0.006) (Fig. 5: gray vs. red).
Discussion
This study used ferumoxytol to determine perfusion 
changes in patients with high grade glioma after treat-
ment with bevacizumab. The results show that after 
treatment with anti-VEGF agent BEV there is a sig-
nificant decrease in GBCA-enhancing volume, and a 
decrease in perfusion using ferumoxytol in the enhancing 
area of high grade gliomas after chemotherapy and radia-
tion therapy but only when the pre-treatment enhancing 
regions of interest (ROIpre) were used. The use of pre-
treatment enhancing regions of interest (ROIpre) over 
which to assess post-BEV perfusion maps increased sen-
sitivity in all cases, suggesting that this method should 
be considered when quantifying blood volume changes 
after BEV. However, given the reduction in mass effect 
known to accompany BEV treatment it is possible that 
tissue shift could account for the difference. In the his-
togram analysis, it becomes clear that the decrease in the 
mean rCBV happens as expected due to BEV treatment, 
quantified by an increase in hypoperfused and a decrease 
in hyperperfused subvolumes. Nearly half of lesions 
changed from high rCBV before the BEV administration 
to low rCBV post-BEV. This is particularly important for 
cases in which perfusion MRI will be used to assess new 
or increasing enhanced areas for possible treatment.
Several publications describe the association between 
high CBV and tumor progression and low CBV and pseu-
doprogression and treatment related changes [8, 22, 23]. 
The ideal cutoff value has been under intense debate 
[4, 6, 24, 25]. We use 1.75 as a threshold rCBV value at 
our institution given significant indications that using 
this threshold for planning subsequent treatment is cor-
related well with overall survival [3]. Given that a sig-
nificant percentage of lesions changed from high rCBV 
before the BEV administration to low rCBV after its 
infusion (44%), it is important to acquire perfusion MRI 
before the administration of BEV if rCBV will be used to 
determine whether a new or increased enhancing lesion 
represents true progression of disease or changes due to 
CRT. Other previously published threshold values range 
from 0.7 to 2.6; had they been utilized in this study, it is 
possible that the interpretation of the effects of bevaci-
zumab on rCBV as it pertains to criteria for pseudopro-
gression, may have been different [6, 24, 25]. Extreme 
threshold values, high or low, would have less impact as 
the majority of cases having values under or above the 
threshold before and after bevacizumab administration 
would increase, respectively.
The RANO treatment response evaluation criteria are 
based on clinical symptoms and conventional MRI (T1-
weighted GBCA-based contrast volume enhancement) 
findings. Treatment related changes and the diagnos-
tic challenge it represents are well known, including the 
impossibility of reliable evaluation with conventional 
MRI. A number of advanced imaging techniques have 
been studied including diffusion, spectroscopy, DCE and 
DSC perfusion MRI and nuclear medicine techniques, 
all with variable results. Our group has shown that cer-
ebral blood volume measurements based on DSC perfu-
sion, particularly in cases where a blood pool agent such 
as ferumoxytol is used, is a reliable method that can be 
used to differentiate between pseudoprogression and real 
tumor progression [3]. In 56% of the lesions, there was 
no significant change in the diagnosis and interpretation 
of the perfusion values. There are several possible alter-
natives for this finding. If baseline rCBV was very high 
before bevacizumab administration and decreased after 
treatment, it is possible that rCBV values did not go 
below the threshold, maybe related to aggressive tumor 
Fig. 1 GBCA-enhancing volume on T1-weighted MRI significantly 
decreased (P = 0.005) post-BEV
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progression with some resistance to the effect of bevaci-
zumab. A floor effect is also possible in areas of tumors 
that are poorly perfused; if rCBV values were already 
very low before bevacizumab administration, an eventual 
decrease in perfusion values will not change the diagno-
sis of pseudoprogression.
Leakage correction is necessary for accurate quantifica-
tion of perfusion MRI using GBCA; rCBV measurements 
using gadoteridol can adequately distinguish between 
patients with treatment related changes versus true pro-
gression only after leakage correction is applied [3]. The 
confounding effect of BEV and the infrequent use of leak-
age correction may be two critical factors contributing 
to the inconsistency in the literature of using rCBV to 
determine disease progression status [4, 26–28]. Finally, 
relative perfusion values from ferumoxytol-based DSC 
in GBM clearly match those in recent reports, without 
the need for leakage correction or preload dosing as is 
Fig. 2 GBM in 44 y/o male: GBCA enhancement on T1-weighted pre- (a, ROIpre) and post-BEV (d, ROIpost). rCBV maps derived from ferumoxytol DSC 
pre- (b) and post-BEV (e) overlaid on the enhancing volume. An overlay of the post-BEV rCBV map on ROIpre can be found in c. “Hot spot” regions are 
indicated by white arrows; note the marked decrease in rCBV between b and c
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Fig. 3 Change in rCBV pre- and post-BEV for each of 21 lesions. A black line indicates a decrease in rCBV, red indicates a decrease in rCBV that passed 
the clinically relevant threshold of 1.75, and the remaining lesions are marked in gray. Values for the entire enhancing volume are shown in a and b. 
c and d depict hot spot changes. a and c depict the rCBV change between pre-BEV measured over ROIpre and post-BEV rCBV measured over ROIpost. 
b and d depict the rCBV change between pre-BEV measured in ROIpre and post-BEV rCBV in ROIpre
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currently necessary for accurate assessment of tumor 
perfusion with GBCA [11].
Lastly, recent reports have showed clear region-specific 
long term deposition of gadolinium in the brain [29]. 
While it is not yet clear whether there are any adverse 
health effects of gadolinium accumulation, these reports 
are serious enough to warrant a FDA safety announce-
ment [30]. Ferumoxytol does not extravasate from the 
blood pool into brain parenchyma nearly as readily as do 
most GBCAs used in clinical practice today. While the 
incidence of serious anaphylaxis risk is approximately 
10 times higher using ferumoxytol compared to most 
GBCAs, the absolute incidence of severe side effects 
remains small, approximately 1:10,000. Current evidence 
and experience indicates that ferumoxytol is a safe and 
available alternative for GBCA for assessment of tumor 
progression versus CRT-related changes.
Limitations of this report include the choice of a single 
slice method for pixel-wise histogram analyses. This tech-
nique is based on the RANO criteria for assessment of 
brain tumor in the clinical practice and for clinical trials, 
but it is possible that important information was missed 
by not using the entire tumor. It is unlikely that results 
would change based on the location of the slice or the use 
of the entire tumor, and single slice measurements are the 
norm in clinical practice. In addition, it is difficult to pre-
cisely control the relative timing of BEV, CRT, and MRI 
exams. While it is plain that the timing of these exams 
with respect to treatment phase can have profound effects 
on results, the cohort in this study was carefully chosen to 
have as narrow a window of timing variability as possible.
Conclusions
In conclusion, due to blood volume reduction caused by 
BEV, the threshold of rCBV  >  1.75, used to differentiate 
high rCBV from low rCBV after CRT, may be confounded 
early after BEV administration and thwart true diagnoses 
of vascular progression, true response, or treatment related 
changes. Ideally, pre-BEV measurements should be used 
and extreme care taken with clinical interpretation of per-
fusion MRI results in any patients who have received BEV, 
even when using an intravascular agent such as ferumoxytol.
Fig. 4 Relationship between rCBV measurements and time interval 
to post-treatment MRI. Top hot spot rCBV measurements in ROIpost 
(filled) and ROIpre (open); y axis is % rCBV reduction, a negative value 
indicates rCBV increase. Bottom mean rCBV over the entire enhancing 
lesion. No significant relationships of rCBV with post-treatment MRI 
time intervals were found (all P > 0.1)
Fig. 5 Distribution of the averaged over all patients’ rCBV voxel 
values before administration of BEV (pre-BEV, gray), after it using the 
pre-BEV volume of enhancement (red, ROIpre) and post-BEV volume 
of enhancement (blue, ROIpost). There is a significant increase in the 
proportion of hypoperfused voxels (P = 0.008) and a significant 
decrease in hyperperfused voxels (P = 0.01) in both ROIs after BEV 
administration
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